CCMR1

Title	CCMR1
Description	A double-blind, randomised placebo-controlled study of the safety & tolerability of a retinoid-X receptor agonist’s ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy: a phase 2a trial.
Status	Active
PI	Prof Siddharthan Chandran
Edinburgh Imaging Collaborator	Prof Adam Waldman
Disease	Multiple Sclerosis (MS)
Facility / resource	EIF RIE
Project type	Multi-centre randomised placebo-control study
Funding	Anne Rowling Clinic

This article was published on 15 Mar, 2019